PERTH: Argenica Therapeutics Limited (ASX: AGN), a biotechnology company developing novel therapeutics to reduce brain tissue death after stroke, provided an update on its Board composition as the Company moves heads into its Phase 1 clinical trial. Today Dr Liz Dallimore, Argenica’s CEO has been appointed to the Board of the Company as Managing Director….